MA48625A - Composés et méthodes de traitement de la douleur viscérale - Google Patents

Composés et méthodes de traitement de la douleur viscérale

Info

Publication number
MA48625A
MA48625A MA048625A MA48625A MA48625A MA 48625 A MA48625 A MA 48625A MA 048625 A MA048625 A MA 048625A MA 48625 A MA48625 A MA 48625A MA 48625 A MA48625 A MA 48625A
Authority
MA
Morocco
Prior art keywords
methods
visceral pain
pain treatment
treatment compounds
compounds
Prior art date
Application number
MA048625A
Other languages
English (en)
Inventor
Cheryl Geraldine Lassen
Marcelo Fabian Piccirillo
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA48625A publication Critical patent/MA48625A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA048625A 2017-05-08 2018-05-08 Composés et méthodes de traitement de la douleur viscérale MA48625A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762503280P 2017-05-08 2017-05-08

Publications (1)

Publication Number Publication Date
MA48625A true MA48625A (fr) 2020-03-18

Family

ID=62245468

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048625A MA48625A (fr) 2017-05-08 2018-05-08 Composés et méthodes de traitement de la douleur viscérale

Country Status (13)

Country Link
US (2) US20200078358A1 (fr)
EP (1) EP3621619B1 (fr)
JP (1) JP7247106B2 (fr)
KR (1) KR20200005614A (fr)
CN (1) CN110709085A (fr)
AU (1) AU2018266145A1 (fr)
BR (1) BR112019023214A2 (fr)
CA (1) CA3062824A1 (fr)
EA (1) EA201992638A1 (fr)
ES (1) ES2956059T3 (fr)
MA (1) MA48625A (fr)
MX (2) MX2019013311A (fr)
WO (1) WO2018208848A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200078358A1 (en) 2017-05-08 2020-03-12 Arena Pharmaceuticals, Inc. Compounds and Methods for Treatment of Visceral Pain
JP2024508514A (ja) * 2021-03-02 2024-02-27 アリーナ ファーマシューティカルズ， インコーポレイテッド 選択的ｃｂ２受容体アゴニストによる処置の方法
WO2023059610A1 (fr) * 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Formes cristallines et processus de préparation de modulateurs des récepteurs cannabinoïdes
US20250387335A1 (en) * 2022-02-02 2025-12-25 Makscientific, Llc Pharmaceutical Compositions, and Preparation and Methods of Use Thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605906A (en) 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5971080A (en) 1997-11-26 1999-10-26 Central Sprinkler Corporation Quick response dry pipe sprinkler system
US7308894B2 (en) 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
IL150302A (en) 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2005123677A1 (fr) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd Utilisation de derives de 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa[a]pentalene a substitution 4-carbonyle comme agonistes du recepteur couple aux proteines g s1p1/edg1 et agents immunosuppresseurs
CA2586011C (fr) 2004-07-12 2011-07-19 Cadila Healthcare Limited Derives tricycliques de la pyrazole en tant que modulateurs de recepteurs cannabinoides
WO2006010379A1 (fr) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Nouveaux derives du thiophene utilises comme agents immunosupresseurs
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2613678A1 (fr) 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Nouveaux ligands des recepteurs des cannabinoides, compositions pharmaceutiques contenant ces ligands, et procede servant a leur preparation
US7597910B2 (en) 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
BRPI0616263A2 (pt) 2005-09-23 2011-06-14 Janssen Pharmaceutica Nv moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
CA2654246A1 (fr) 2006-07-04 2008-01-10 Janssen Pharmaceutica N.V. Agonistes cannabinoides de type benzimidazole portant un groupement heterocyclique substitue
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (fr) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Composés qui modulent le récepteur cb2
AU2007315848A1 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
EP2120938A4 (fr) 2006-12-20 2010-12-08 Merck Sharp & Dohme Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
WO2008109007A1 (fr) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Phénanthridines pontées
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
WO2008157500A1 (fr) 2007-06-17 2008-12-24 Kalypsys, Inc. Modulateurs du récepteur cannabinoïde à base d'aminoquinazoline pour le traitement de maladies
EA201000046A1 (ru) 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (fr) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Ligands de récepteur cb2 pour le traitement de la douleur
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
CN102282147B (zh) 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 二环吡唑并-杂环
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
EP2470508A1 (fr) * 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Modulateurs des récepteurs de cannabinoïdes
MX392150B (es) 2011-02-25 2025-03-21 Arena Pharm Inc Moduladores de receptores canabinoides.
JP5945554B2 (ja) * 2011-02-25 2016-07-05 アリーナ ファーマシューティカルズ， インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター）
WO2012116278A1 (fr) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Modulateurs des récepteurs de cannabinoïdes
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2016085941A1 (fr) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Procédés de préparation de modulateurs des récepteurs de cannabinoïdes
WO2017039643A1 (fr) 2015-09-01 2017-03-09 Arena Pharmaceuticals, Inc. Internalisation de récepteur cb2
CN109310673A (zh) * 2016-04-10 2019-02-05 艾尼纳制药公司 用选择性cb2受体激动剂治疗的方法
US20200078358A1 (en) 2017-05-08 2020-03-12 Arena Pharmaceuticals, Inc. Compounds and Methods for Treatment of Visceral Pain
WO2018208847A1 (fr) * 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compositions et méthodes pour le traitement de la douleur résultant de la maladie inflammatoire chronique de l'intestin
US12357604B2 (en) * 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
JP2024508514A (ja) * 2021-03-02 2024-02-27 アリーナ ファーマシューティカルズ， インコーポレイテッド 選択的ｃｂ２受容体アゴニストによる処置の方法
WO2023059610A1 (fr) * 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Formes cristallines et processus de préparation de modulateurs des récepteurs cannabinoïdes

Also Published As

Publication number Publication date
US20200078358A1 (en) 2020-03-12
CN110709085A (zh) 2020-01-17
EP3621619B1 (fr) 2023-06-28
US12201633B2 (en) 2025-01-21
KR20200005614A (ko) 2020-01-15
AU2018266145A1 (en) 2019-11-28
WO2018208848A1 (fr) 2018-11-15
MX2022008265A (es) 2022-08-04
ES2956059T3 (es) 2023-12-12
EP3621619A1 (fr) 2020-03-18
CA3062824A1 (fr) 2018-11-15
MX2019013311A (es) 2020-08-03
EA201992638A1 (ru) 2020-03-18
JP2020518649A (ja) 2020-06-25
US20230033510A1 (en) 2023-02-02
JP7247106B2 (ja) 2023-03-28
BR112019023214A2 (pt) 2020-05-26
EP3621619C0 (fr) 2023-06-28

Similar Documents

Publication Publication Date Title
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
MA46102A (fr) Composés de tétracycline et méthodes de traitement
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
EP3613073A4 (fr) Traitement de puces
EP3589659A4 (fr) Composés et méthodes de traitement du cancer
EP3645121A4 (fr) Méthodes de traitement de la maladie de huntington
EP3448504A4 (fr) Traitement de stimulation cérébrale pour dépression
EP3448263A4 (fr) Traitement électrothérapeutique
EP3946345A4 (fr) Méthodes de traitement de la douleur neuropathique
EP3370721A4 (fr) Traitement de l'ostéoarthrite
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3752161A4 (fr) Méthodes de traitement de la fibrose
EP3599983A4 (fr) Endoscopes et méthodes de traitement
EP3630101A4 (fr) Méthodes de traitement de maladies
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
EP3606531A4 (fr) Méthodes de traitement du cancer
EP3773633A4 (fr) Méthodes de traitement de glioblastomes
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
EP3745862A4 (fr) Méthodes de traitement de pathologies fibrotiques
EP3313417A4 (fr) Méthodes de traitement de troubles auto-immuns et allo-immuns
EP3383857A4 (fr) Composés et méthodes de traitement d'infections bactériennes
EP3852816A4 (fr) Méthodes de traitement de cancer
MA46353A (fr) Méthodes de traitement de l'infertilité féminine